This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
G-protein-coupled receptor (GPCR) A large family of membrane receptors that activate intracellular signaling pathways through G-proteins. GPCRs are critical in neurotransmission, hormone signaling, and sensory perception. Granule cell A small neuron found in the cerebellum, olfactory bulb, and dentate gyrus of the hippocampus. Granule cells play important roles in sensory and motor information processing. Granulomatosis with polyangiitis An autoimmune disease that can affect the central nervous system, sometimes causing neuropathy, headaches, or stroke-like symptoms due to vascular inflammation. Grasp reflex A primitive reflex seen in infants where touching the palm induces the hand to close. Persistence in adults may indicate frontal lobe damage. Gray matter Brain tissue composed primarily of neuronal cell bodies, dendrites, and unmyelinated axons. It is responsible for information processing and synaptic transmission. Growth cone A dynamic, motile structure at the tip of a developing axon or dendrite that guides neuronal growth by sensing molecular cues in the environment. Growth factor A naturally occurring protein that stimulates cell growth, differentiation, and survival. Examples include BDNF, NGF, and EGF in neural development and repair. Gustatory cortex The brain area responsible for processing taste information, primarily located in the insular and frontal opercular regions. Gyri (singular gyrus) The raised ridges or folds of the cerebral cortex. They increase the brain’s surface area and are separated by sulci (grooves).
==== Angiogenesis and obesity ==== Studies have disagreed about the effects of FFAR2 on adipogenesis (i.e., formation of fat cells and fat tissue from precursor cells) as well as on the development of obesity. The inconsistencies reported by different research groups need to be resolved through further research in order to develop a clear picture of the actions that FFAR2 has on adipogenesis and obesity.
==== Usually acquired ==== Melanocytic nevus Melanocytic nevi can be categorized based on the location of melanocytic cells Junctional: epidermis Intradermal: dermis Compound: epidermis and dermis Atypical (dysplastic) nevus: This type of nevus must be diagnosed based on histological features. Clinically, atypical nevi are characterized by variable pigmentation and irregular borders. Becker's nevus Blue nevus (rarely congenital): A classic blue nevus is usually smaller than 1 cm, flat, and blue-black in color. Hori's nevus Nevus spilus (speckled lentiginous nevus): This lesion includes dark speckles within a tan-brown background. Pigmented spindle cell nevus Spitz nevus Zosteriform lentiginous nevus
=== DNA chips === Early biochips were based on the idea of a DNA microarray, e.g., the GeneChip DNAarray from Affymetrix, which is a piece of glass, plastic or silicon substrate, on which pieces of DNA (probes) are affixed in a microscopic array. Similar to a DNA microarray, a protein array is a miniature array where a multitude of different capture agents, most frequently monoclonal antibodies, are deposited on a chip surface; they are used to determine the presence and/or amount of proteins in biological samples, e.g., blood. A drawback of DNA and protein arrays is that they are neither reconfigurable nor scalable after manufacture. Digital microfluidics has been described as a means for carrying out Digital PCR.
The Decision of the third plenary session of the 18th Central Committee announced "market forces" would begin to play a "decisive" role in allocating resources. This meant that the state would gradually reduce its involvement in the distribution of capital, and restructure state-owned enterprises (SOEs) to allow further competition, potentially by attracting foreign and private sector players in industries previously highly regulated. This policy aimed to address the bloated state sector that had unduly profited from re-structuring by purchasing assets at below-market prices, assets no longer being used productively. However, by 2017, Xi's promise of economic reforms was said to have stalled by external observers. In 2015, the Chinese stock market bubble popped, which led Xi to use state forces to fix it. China's economy has grown under Xi, more than doubling from CN¥54.8 trillion (US$8.7 trillion) in 2012 to CN¥140.2 trillion (US$20.1 trillion) in 2025, while China's nominal GDP per capita increased from CN¥40,431 (US$6,408) in 2012 to CN¥99,665 (US$14,318) in 2025, surpassing the world average in 2021, though growth has slowed from 7.9% in 2012 to 5% in 2025. Xi has increased state control over the economy, voicing support for SOEs, while also supporting the private sector. CCP control of SOEs has increased, while limited steps towards market liberalization, such as increasing mixed ownership of SOEs were undertaken. Under Xi, an increasing number of private companies have established Party branches.
Sources: en.wikipedia.org
=== Bacterial homeostasis === AMPylation is involved in bacterial homeostasis. The most famous example is AMPylator GS-ATase (GlnE), which contributes in complex regulation of nitrogen metabolism through AMPylation of glutamine synthetase that was introduced in the AMPylation and DeAMPylation parts. Another example of AMPylators that play a role in bacterial homeostasis is the class I Fic AMPylators (FicT), which modifies the GyrB subunit of DNA gyrase, the conserved tyrosine residue for ATP binding of ParE subunit at Topoisomerase IV. This DNA gyrase inactivation by AMPylation leads to the activation of SOS response, which is the cellular response to DNA damage. The activity of FicT AMPylation is reversible and only leads to growth arrest, but not cell death. Therefore, FicT AMPylation plays a role in regulating cell stress, which is shown in the Wolbachia bacteria that the level of FicT increases in response to doxycycline. A Class III Fic AMPylator NmFic of N. meningtidis is also found to modify AMPylate GyrB at the conserved tyrosine for ATP binding. This shows that Fic domains are highly conserved that indicates the important role of AMPylation in regulating cellular stress in bacteria. The regulation of NmFic involves the concentration-dependent monomerization and autoAMPylation for activation of NmFic activity.
In an announcement that surprised some foreign experts, the joint investigation concluded that early transmission via the cold chain of frozen products was "possible". In March 2021, the WHO published a written report with the results of the study. The joint team stated that there are four scenarios for introduction:
The film received mixed reviews from critics, but DiCaprio's performance was praised and earned him the AACTA Award for Best Actor in a Leading Role. Critic Rafer Guzman of Newsday wrote that DiCaprio was not only "tough [...] but also vulnerable, touching, funny, a faker, a human. It's a tremendous, hard-won performance." Matt Zoller Seitz of Roger Ebert's website described his performance as "the movie's greatest and simplest special effect", and "iconic—maybe his career best". The film grossed $353 million worldwide, more than three times its budget. Three films were produced by DiCaprio under Appian Way in 2013—the ensemble crime thriller Runner Runner, which The Guardian's Xan Brooks described as "a lazy, trashy film that barely goes through the motions"; the commercially failed thriller Out of the Furnace; and the black comedy-drama The Wolf of Wall Street. DiCaprio reunited with Scorsese for the fifth time in The Wolf of the Wall Street, a film based on the life of stockbroker Jordan Belfort (played by DiCaprio), who was arrested in the late 1990s for securities fraud and money laundering. DiCaprio wanted to play Belfort ever since he had read his autobiography and won a bidding war with Warner Bros. against Brad Pitt and Paramount Pictures for the rights to Belfort's memoir in 2007. He was fond of Belfort's honest and unapologetic portrayal of his actual experiences in the book, and was inspired by the 2008 financial crisis to make the film. The Wolf of Wall Street received positive reviews for Scorsese's and DiCaprio's work together.
== Examples of GxPs == Good agricultural and collection practices, or GACP(s) Good agricultural practice, or GAP Good auditing practice, or GAP Good automated laboratory practice, or GALP Good automated manufacturing practice, or GAMP Good business practice, or GBP Good cell culture practice, or GCCP Good clinical data management practice, or GCDMP Good clinical laboratory practice, or GCLP Good clinical practice, or GCP Good documentation practice, or GDP, or GDocP (to distinguish from "good distribution practice") Good distribution practice, or GDP Good engineering practice, or GEP Good financial practice, or GFP Good guidance practice, or GGP Good hygiene practice, or GHP Good laboratory practice, or GLP Good machine learning practice, or GMLP Good management practice, or GMP Good manufacturing practice, or GMP Good microbiological practice, or GMiP Good participatory practice, or GPP Good pharmacovigilance practice, or GPvP or even GVP Good pharmacy practice, or GPP Good policing practice, or GPP Good recruitment practice, or GRP Good research practice, or GRP Good safety practice, or GSP Good storage practice, or GSP Good tissue practice, or GTP
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.